Characterization of a membrane-associated estrogen receptor in breast cancer cells and its contribution to hormone therapy resistance using a novel selective ligand.
Antineoplastic Agents, Hormonal
/ therapeutic use
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Cell Membrane
/ metabolism
Cell Proliferation
Drug Resistance, Neoplasm
Estradiol
/ metabolism
Estrogens
/ metabolism
Female
Gene Expression Regulation, Neoplastic
Humans
Ligands
Quantum Dots
/ metabolism
Receptors, Estrogen
/ metabolism
Transcriptome
Breast cancer
Cell growth
Estrogen receptor activity
Hormone therapy resistance
Membrane-associated estrogen receptor
Phosphorylation pathways
Specific ligand
Journal
The Journal of steroid biochemistry and molecular biology
ISSN: 1879-1220
Titre abrégé: J Steroid Biochem Mol Biol
Pays: England
ID NLM: 9015483
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
27
01
2020
revised:
23
03
2020
accepted:
03
04
2020
pubmed:
15
4
2020
medline:
5
11
2020
entrez:
15
4
2020
Statut:
ppublish
Résumé
The estrogen receptor (ER) plays a role in the progression of hormone-dependent breast cancer and is a hormone therapy target. Estrogen acts as a transcription factor (genomic action) and also produces a quick non-genomic reaction through intracellular signaling pathways. The membrane associated ER (mER) may regulate both these signals and hormone therapy resistance. However, the details remain unclear because a reliable method to distinguish the signals induced by the estradiol (E2)-mER and E2-nuclear ER complex has not been established. In the present study, we prepared the novel ligand Qdot-6-E2, selective for mER, by coupling E2 with insoluble quantum dot nano-beads. We investigated the characteristics of mER signaling pathways and its contribution to hormone therapy resistance using different cell lines including estrogen depletion resistant (EDR) cells with different mechanisms. Qdot-6-E2 stimulated proliferation of nuclear ER-positive cells, but nuclear ER-negative cells showed no response. In addition, Qdot-6-E2 indirectly activated nuclear ER and increased mRNA expression of target genes. We confirmed that E2 was not dissociated from Qdot-6-E2 using a mammalian one-hybrid assay. We visually demonstrated that Qdot-6-E2 acts from the outside of cells. The gene expression profile induced by Qdot-6-E2-mER was different from that induced by E2-nuclear ER. The effect of anti-ER antibody, the GFP-ER fusion protein localization, and the effect of palmitoyl acyltransferase inhibitor also indicated the existence of mER. Regarding intracellular phosphorylation signaling pathways, the MAPK (Erk 1/2) and the PI3K/Akt pathways were both activated by Qdot-6-E2. In EDR cells, only nuclear ER-positive cells showed increased cell proliferation with increased localization of ERα to the membrane fraction. These findings suggested that Qdot-6-E2 reacts with ERα surrounding the cell membrane and that mER signals help the cells to survive under estrogen-depleted conditions by re-localizing the ER to use trace amounts of E2 more effectively. We expect that Qdot-6-E2 is a useful tool for studying the mER.
Identifiants
pubmed: 32289430
pii: S0960-0760(20)30029-7
doi: 10.1016/j.jsbmb.2020.105671
pii:
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Estrogens
0
Ligands
0
Receptors, Estrogen
0
Estradiol
4TI98Z838E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105671Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.